Section Arrow
RNA.NASDAQ
- Avidity Biosciences
Quotes are at least 15-min delayed:2025/07/21 06:57 EDT
Pre Market
Last
 --
-- (--)
Bid
33.51
Ask
34.5
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 33.76
-0.28 (-0.82%)
Day High 
35.14 
Prev. Close
34.04 
1-M High
35.2935 
Volume 
2.73M 
Bid
33.51
Ask
34.5
Day Low
33.47 
Open
34.37 
1-M Low
27.705 
Market Cap 
4.10B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 31.43 
20-SMA 30.34 
50-SMA 30.7 
52-W High 56 
52-W Low 21.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.00/-3.48
Enterprise Value
4.11B
Balance Sheet
Book Value Per Share
11.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.90M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.97 -0.31 -13.60%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.01 -1.065 -7.57%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.23 +0.39 +6.68%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.11 +0.19 +3.21%
Quotes are at least 15-min delayed:2025/07/21 06:57 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.